Oral capecitabine: Bridging the Atlantic divide in colon cancer treatment

Seminars in Oncology

Volumn 32, Issue 1 SPEC. ISS., 2005, Pages 43-51

  Van Cutsem, Eric ^a   Verslype, Chris ^a   Tejpar, Sabine ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; UFT;

ALOPECIA; ARTICLE; ASTHENIA; BOLUS INJECTION; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; COLON CANCER; COMPARATIVE STUDY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEPATOBILIARY DISEASE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; INFUSION; KAPLAN MEIER METHOD; LIVER TOXICITY; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL;

EID: 13844294269     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.09.028     Document Type: Article

References (55)

1. L.B. Saltz, J.V. Cox, C. Blanke Irinotecan Study Group Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 343 2000 905 914
2. H. Hurwitz, L. Fehrenbacher, T. Cartwright Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC) Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC Proc Am Soc Clin Oncol 22 2003 906i (abstr 3646)
3. J.Y. Douillard, D. Cunningham, A.D. Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer A multicentre randomised trial Lancet 355 2000 1041 1047
4. A. de Gramont, A. Figer, M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947
5. M. Miwa, M. Ura, M. Nishida Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1998 1274 1281
6. J. Schüller, J. Cassidy, E. Dumont Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 2000 291 297
7. M.M. Borner, P. Schöffski, R. de Wit Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin A randomised crossover trial in advanced colorectal cancer Eur J Cancer 38 2002 349 358
8. G. Liu, E. Franssen, M. Fitch Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 1997 110 115
9. E. Van Cutsem, M. Findlay, B. Osterwalder Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer Results of a randomized phase II study J Clin Oncol 18 2000 1337 1345
10. E. Van Cutsem, C. Twelves, J. Cassidy Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer Results of a large phase III study J Clin Oncol 19 2001 4097 4106
11. P. Hoff, R. Ansari, G. Batist Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer Results of a randomized phase III study J Clin Oncol 19 2001 2282 2292
12. E. Van Cutsem, P. Hoff, P. Harper Oral capecitabine versus intravenous 5-fluorouracil and leucovorin Integrated efficacy data and novel analyses from two large, randomised, phase III trials Br J Cancer 90 2004 1190 1197
13. Meta-analysis Group in Cancer Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer J Clin Oncol 16 1998 301 308
14. A. de Gramont, J.F. Bosset, C. Milan Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer A French intergroup study J Clin Oncol 15 1997 808 815
15. C.H. Köhne, J. Wils, M. Lorenz Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer European Organization of Research and Treatment of Cancer Gastrointestinal Group study 40952 J Clin Oncol 21 2003 3721 3728
16. J. Cassidy, C. Twelves, E. Van Cutsem First-line oral capecitabine therapy in metastatic colorectal cancer A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin Ann Oncol 13 2002 566 575
17. IMPACT: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345:939-9441, 995
18. E. Van Cutsem, M. Dicato, J. Wils Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001) Eur J Cancer 38 2002 1429 1436
19. H.T. Arkenau, A. Bermann, K. Rettig 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer Long-term follow-up results of the adjCCA-01 trial Ann Oncol 14 2003 395 399
20. T. André, P. Colin, C. Louvet Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer Results of a randomized trial J Clin Oncol 21 2003 2896 2903
21. D.G. Haller, P. Catalano, J.S. Macdonald Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer Five-year final report of int-0089 Proc Am Soc Clin Oncol 17 1998 256a (abstr 982)
22. A. Haydon Adjuvant chemotherapy in colon cancer What is the evidence? Int Med J 33 2003 119 124
23. A. Grothey, L. Kellermann, H.J. Schmoll [Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms] Med Klin (Munich) 97 2002 270 277
24. S. Hensley Alford, M. Ulcickas-Yood, M. Jankowski Stage III colon cancer in the elderly Adjuvant therapy and survival Proc Am Soc Clin Oncol 22 2003 748 (abstr 3008)
25. J. Cassidy, W. Scheithauer, J. McKendrick Capecitabine vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-act study) Positive efficacy results of a phase III trial Proc Am Soc Clin Oncol 22 2004 247 (abstr 3509)
26. W. Scheithauer, J. McKendrick, S. Begbie Oral capecitabine as an alternative to i.v. 5-FU-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial Ann Oncol 14 2003 1735 1743
27. T. Hickish, C. Boni, J. Tabernero Oxaliplatin/5-fluorouracil/leucovorin in stage II and III colon cancer Updated results of the international randomized "MOSAIC" trial Proc Am Soc Clin Oncol GI Cancer Symp 46 2004 (abstr 211)
28. M.L. Rothenberg, N.J. Meropol, E.A. Poplin Mortality associated with irinotecan plus bolus fluorouracil/leucovorin summary findings of an independent panel J Clin Oncol 19 2001 3801 3807
29. R.F. Morton, R.M. Goldberg, D.J. Sargent Oxaliplatin (OXAL) or CPT-11 combined with 5FU/leucovorin (LV) in advanced colorectal cancer (CRC) An NCCTG/CALGB study Proc Am Soc Clin Oncol 20 2001 125a (abstr 495)
30. R.M. Goldberg, D.J. Sargent, R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30
31. J. Cassidy, J. Tabernero, C. Twelves XELOX (capecitabine plus oxaliplatin) Active first-line therapy for patients with metastatic colorectal cancer J Clin Oncol 22 2004 2084 2091
32. E. Van Cutsem, C. Twelves, J. Tabernero XELOX mature results of a mulitnational, phase II trial of capecitabine plus oxaliplatin, an effective first-line option for patients with metastatic colorectal cancer Proc Am Soc Clin Oncol 22 2003 255 (abstr 1023)
33. E. Dìaz-Rubio, T.R. Evans, J. Tabernero Capecitabine (Xeloda) in combination with oxaliplatin A phase I, dose-escalation study in patients with advanced or metastatic solid tumors Ann Oncol 13 2002 558 565
34. A.F. Shields, M.M. Zalupski, J.L. Marshall Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine Cancer 100 2004 531 537
35. M.M. Borner, D. Dietrich, R. Stupp Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer J Clin Oncol 20 2002 1759 1766
36. E. Chu, E. Diaz-Rubio, J. Marshall Economic analysis of potential medical cost savings of XELOX (capecitabine and oxaliplatin combination) in metastatic colorectal cancer (MCRC) Proc Am Soc Clin Oncol 22 2003 269 (abstr 1080)
37. E. Van Cutsem, P. Beale, J.P. Delord Tarceva (erlotinib) in combination with Xeloda (capecitabine) and oxaliplatin in patients with metastatic colorectal cancer (CRC) A phase I dose-escalation trial Clin Cancer Res 9 suppl 2003 6095s (abstr 109)
38. G. Hapke, S. Cao, Y.M. Rustum Enhanced antitumour activity of Xeloda by irinotecan in nude mice bearing human A253 and FaDu head and neck xenografts Proc Am Assoc Cancer Res 42 2001 86 (abstr 464)
39. M. Tewes, N. Schleucher, W. Achterrath Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer Results of an extended phase I study dagger Ann Oncol 14 2003 1442 1448
40. D. Kerr, W.W. Ten Bokkel Huinink, D. Ferry A phase I/II study of CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC) Proc Am Soc Clin Oncol 21 2002 161a (abstr 643)
41. J.P. Delord, J. Pierga, F. Bertheaut-Cvitkovic Dose escalation and pharmacokinetic study of capecitabine and irinotecan (CPT-11) in gastro-intestinal (GI) tumours Eur J Cancer 37 suppl 6 2001 76 (abstr 272)
42. Y.Z. Patt, J. Leibmann, D. Diamandidis Capecitabine plus irinotecan (XELIRI) in first-line metastatic colorectal cancer (MCRC) Update on a phase II trial Eur J Cancer 1 suppl 5 2003 S93 (abstr 304)
43. A. Munoz, A. Salut, P. Escudero Irinotecan (CPT-11) and capecitabine (C) as first-line treatment of locally advanced or metastatic colorectal cancer (CRC) Proc Am Soc Clin Oncol 22 2003 317 (abstr 1271)
44. M.M. Borner, D. Dietrich, R. Popescu A randomized phase II trial of capecitabine (CAP) and two different schedules of irinotecan (IRI) in first-line treatment of metastatic colorectal cancer (MCC) Proc Am Soc Clin Oncol 22 2003 266 (abstr 1068)
45. P. Gold, T. Godfrey, M. Dhami Capecitabine and irinotecan as 1st line therapy for patients with metastatic colorectal cancer (MCRC) Phase II study preliminary results Proc Am Soc Clin Oncol 22 2003 288 (abstr 1158)
46. N. Meropol, P. Gold, B. Diasio Correlation of thymidine phosphorylase (TP), thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) expression in primary and metastatic sites with response to capecitabine plus irinotecan in patients with colorectal cancer Proc Am Soc Clin Oncol 23 2004 250 (abstr 3520)
47. M. Yanagisawa, K.F. Ouchi, Y. Tanaka Optimal dosing schedule for combination therapy with capecitabine and irinotecan in a human colorectal cancer (CRC) xenograft model Eur J Cancer 1 suppl 5 2003 S81 (abstr 264)
48. A. Grothey, K. Jordan, O. Kellner Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC) Updated results of a randomized phase II trial Eur J Cancer 1 suppl 5 2003 S90 (abstr 295)
49. N. Sawada, T. Ishikawa, F. Sekiguchi X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts Clin Cancer Res 5 1999 2948 2953
50. J. Dunst, T. Reese, T. Hoelscher Preoperative radiochemotherapy with capecitabine (Xeloda) in locally advanced rectal cancer A phase II study Eur J Cancer 1 suppl 5 2003 S86 (abstr 282)
51. E. Lin, J. Skibber, M. Rodriguez A phase II study of capecitabine and radiotherapy plus concomitant boost in patients (pts) with locally advanced rectal cancer (LARC) Preliminary safety analysis Proc Am Soc Clin Oncol 22 2003 287 (abstr 1152)
52. I. Kocakova, S. Spelda, M. Svoboda Combined therapy of locally advanced rectal adenocarcinoma with capecitabine and concurrent radiotherapy Proc Am Soc Clin Oncol 22 2003 322 (abstr 1295)
53. R. Glynne-Jones, D. Sebag-Montefiore, A. McDonald Phase I/II study of preoperative radiation and capecitabine in combination with oxaliplatin in locally advanced rectal cancer The SOCRATES study Proc Am Soc Clin Oncol 22 2003 292 (abstr 1174)
54. C. Rodel, G.G. Grabenbauer, T. Papadopoulos Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer J Clin Oncol 21 2003 3098 3104
55. A. Kennedy, Y. Kwok, S. Batko-Yovino A phase I study of preoperative capecitabine, irinotecan concurrent with radiation therapy for resectable rectal cancer Proc Am Soc Clin Oncol GI Cancer Symp 173 2004 (abstr 268)